NKGen Biotech

NKGen Biotech FCF Growth

The Year-over-Year Free Cash Flow Growth of NKGen Biotech (NKGN) as of Nov 22, 2026 is 5.07 %. In the previous year, Year-over-Year Free Cash Flow Growth was 3.19 % — a change of 59.07% (higher).

FCF Growth

5.07 %

YoY

59.07%

Last updated:

Year-over-Year Free Cash Flow Growth of NKGen Biotech is 2025 5.07 % . Year-over-Year Free Cash Flow Growth of NKGen Biotech was 2024 3.19 % . It decreases by 59.07% higher compared to the previous year.

The NKGen Biotech FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2022
-13.56 USD
Jan 1, 2023
3.19 USD
Jan 1, 2025
5.07 USD
The NKGen Biotech FCF Growth history
YEARFCF GrowthYoY
5.07 %+59.07%
3.19 %-123.50%
-13.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

Year-over-Year Free Cash Flow Growth of NKGen Biotech is 5.07 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's NKGen Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — NKGen Biotech

All Key Metrics — NKGen Biotech